|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TROAP |
Gene summary for TROAP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TROAP | Gene ID | 10024 |
| Gene name | trophinin associated protein | |
| Gene Alias | TASTIN | |
| Cytomap | 12q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | Q12815 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10024 | TROAP | S016 | Human | Liver | HCC | 2.97e-13 | 6.65e-01 | 0.2243 |
| 10024 | TROAP | S027 | Human | Liver | HCC | 3.40e-03 | 5.81e-01 | 0.2446 |
| 10024 | TROAP | S028 | Human | Liver | HCC | 7.94e-11 | 5.97e-01 | 0.2503 |
| 10024 | TROAP | S029 | Human | Liver | HCC | 1.18e-08 | 5.77e-01 | 0.2581 |
| 10024 | TROAP | C04 | Human | Oral cavity | OSCC | 3.58e-20 | 1.54e+00 | 0.2633 |
| 10024 | TROAP | C21 | Human | Oral cavity | OSCC | 3.50e-24 | 1.17e+00 | 0.2678 |
| 10024 | TROAP | C30 | Human | Oral cavity | OSCC | 3.37e-37 | 2.11e+00 | 0.3055 |
| 10024 | TROAP | C38 | Human | Oral cavity | OSCC | 2.51e-06 | 1.09e+00 | 0.172 |
| 10024 | TROAP | C43 | Human | Oral cavity | OSCC | 6.00e-07 | 2.35e-01 | 0.1704 |
| 10024 | TROAP | C46 | Human | Oral cavity | OSCC | 2.81e-04 | 2.86e-01 | 0.1673 |
| 10024 | TROAP | C51 | Human | Oral cavity | OSCC | 2.73e-15 | 9.60e-01 | 0.2674 |
| 10024 | TROAP | C57 | Human | Oral cavity | OSCC | 1.75e-03 | 3.46e-01 | 0.1679 |
| 10024 | TROAP | C08 | Human | Oral cavity | OSCC | 3.91e-07 | 4.95e-01 | 0.1919 |
| 10024 | TROAP | LN38 | Human | Oral cavity | OSCC | 7.79e-03 | 9.42e-01 | 0.168 |
| 10024 | TROAP | LN46 | Human | Oral cavity | OSCC | 4.10e-06 | 4.22e-01 | 0.1666 |
| 10024 | TROAP | LP15 | Human | Oral cavity | LP | 3.38e-02 | 9.91e-01 | 0.2174 |
| 10024 | TROAP | SYSMH2 | Human | Oral cavity | OSCC | 1.31e-07 | 5.11e-01 | 0.2326 |
| 10024 | TROAP | SYSMH3 | Human | Oral cavity | OSCC | 5.11e-06 | 2.32e-01 | 0.2442 |
| 10024 | TROAP | P5_S10_cSCC | Human | Skin | cSCC | 9.41e-05 | 9.92e-02 | -0.299 |
| 10024 | TROAP | P1_cSCC | Human | Skin | cSCC | 1.91e-06 | 3.17e-01 | 0.0292 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TROAP | SNV | Missense_Mutation | c.1457N>G | p.Ser486Cys | p.S486C | Q12815 | protein_coding | deleterious(0.01) | possibly_damaging(0.799) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TROAP | SNV | Missense_Mutation | c.329C>T | p.Ala110Val | p.A110V | Q12815 | protein_coding | deleterious(0.02) | benign(0.023) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| TROAP | SNV | Missense_Mutation | c.257G>T | p.Ser86Ile | p.S86I | Q12815 | protein_coding | deleterious(0) | benign(0.118) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TROAP | SNV | Missense_Mutation | novel | c.1396N>A | p.Val466Ile | p.V466I | Q12815 | protein_coding | tolerated(0.19) | benign(0.14) | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
| TROAP | SNV | Missense_Mutation | c.2024N>G | p.Ser675Cys | p.S675C | Q12815 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-C8-A137-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| TROAP | deletion | Frame_Shift_Del | novel | c.233delN | p.Thr78AsnfsTer41 | p.T78Nfs*41 | Q12815 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TROAP | deletion | Frame_Shift_Del | novel | c.191delN | p.Asp64ValfsTer55 | p.D64Vfs*55 | Q12815 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| TROAP | SNV | Missense_Mutation | novel | c.77N>G | p.Ser26Cys | p.S26C | Q12815 | protein_coding | tolerated(0.12) | benign(0.118) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| TROAP | SNV | Missense_Mutation | c.699N>C | p.Glu233Asp | p.E233D | Q12815 | protein_coding | tolerated(0.35) | benign(0.022) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| TROAP | SNV | Missense_Mutation | c.2275N>C | p.Glu759Gln | p.E759Q | Q12815 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |